Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Pediatric Transplants

Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders

Bone Marrow Transplantation volume 42, pages 83–91 (2008)Cite this article

Abstract

We performed quantitative PCR-based serial chimerism testing of whole blood (WB) and CD3+ cells and retrospectively correlated the results of chimerism tests and the risk of graft loss in children undergoing transplant for non-malignant disorders. Twenty-four children were included in this study. All patients initially engrafted; subsequently, 12% lost the graft, 21% achieved complete donor chimerism and 67% had mixed chimerism (MC). Patients underwent delayed taper of cyclosporine (CsA) if they had MC. Overall survival was 87±7% (s.d.) at 5-years post transplant, and it was not affected by chimerism status. Both WB and CD3+ chimerism showed significant fluctuations with a peak in autologous cell signal occurring at a median of 7 months for WB and 2 months for CD3+ cells. Initial post transplant chimerism percentage in either WB or CD3+ lineage was not related to graft loss. Increasing MC to >30% host cells was seen in 33% of patients, and it was related to increased risk of graft loss, as previously published. However, 63% of children with increasing MC did not lose their graft. Additional studies of post transplant chimerism are required to improve our ability to accurately identify children at risk of graft loss following transplant for non-malignant disorders.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Baron F, Baker J, Storb R, Gooley T, Sandmaier B, Maris M et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104: 2254–2262.

    Article  CAS  PubMed  Google Scholar 

  2. Baron F, Little MT, Storb R . Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity nonmyeloablative conditioning. Blood Rev 2005; 19: 153–164.

    Article  PubMed  Google Scholar 

  3. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234–3241.

    CAS  PubMed  Google Scholar 

  4. Hoelle W, Beck JF, Dueckers G, Kreyenberg H, Lang P, Gruhn B et al. Clinical relevance of serial quantitative analysis of hematopoietic chimerism after allogeneic stem cell transplantation in children for severe aplastic anemia. Bone Marrow Transplant 2004; 33: 219–223.

    Article  CAS  PubMed  Google Scholar 

  5. Matthes-Martin S, Lion T, Haas OA, Frommlet F, Daxberger H, Konig M et al. Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection. Leukemia 2003; 17: 1934–1942.

    Article  CAS  PubMed  Google Scholar 

  6. Hill R, Peterson FB, Storb R, Appelbaum F, Doney K, Dahlberg S et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986; 67: 811–816.

    CAS  PubMed  Google Scholar 

  7. Jacobsohn D, Duerst R, Tse W, Kletzel M . Reduced intensity haematopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004; 364: 156–162.

    Article  PubMed  Google Scholar 

  8. Horn B, Baxter-Lowe L-A, Englert L, McMillan A, Quinn M, DeSantes K et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 2006; 37: 263–269.

    Article  CAS  PubMed  Google Scholar 

  9. Ringden O, Remberger M, Svenberg P, Svahn B-M, Dahllof G, Gustafsson B et al. Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. Bone Marrow Transplant 2007; 39: 383–388.

    Article  CAS  PubMed  Google Scholar 

  10. Kikuta A, Ito M, Mochizuki K, Akaihata M, Nemoto K, Sano H et al. Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe organ dysfunction. Bone Marrow Transplant 2006; 38: 665–669.

    Article  CAS  PubMed  Google Scholar 

  11. Willasch A, Hoelle W, Kreyenberg H, Niethammer D, Handgretinger R, Lang P et al. Outcome of allogeneic stem cell transplantation in children with non-malignant disease. Haematologica 2006; 91: 788–794.

    PubMed  Google Scholar 

  12. Ortega M, Eacudero T, Caballin MR, Olive T, Ortega JJ, Coll MD . Follow-up of chimerism in children with hematological diseases after allogeneic hematopoietic progenitor cell transplants. Bone Marrow Transplant 1999; 24: 81–87.

    Article  CAS  PubMed  Google Scholar 

  13. Andreani M, Nesci S, Lucarelli G, Tonucci P, Rapa S, Angelucci E et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000; 25: 401–404.

    Article  CAS  PubMed  Google Scholar 

  14. Andreani M, Manna M, Lucarelli G, Tonucci P, Agostinelli F, Ripalti M et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996; 87: 3494–3499.

    CAS  PubMed  Google Scholar 

  15. Nesci S, Manna M, Pattorini P, Graziosi G, Lucarelli G . Mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 143–146.

    CAS  PubMed  Google Scholar 

  16. Walters MC, Patience M, Leisenring W, Rogers ZR, Aquino VM, Buchanan GR et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001; 7: 665–673.

    Article  CAS  PubMed  Google Scholar 

  17. Vermylen C, Cornu G, Ferster A, Brichard B, Ninane J, Ferrant A et al. Haematopoietic stem cell transplantation for sickle cell anemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22: 1–6.

    Article  CAS  PubMed  Google Scholar 

  18. Przepiorka D, Wiesdorf D, Martini P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  19. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man: long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  20. Scharf S, Smith A, Hansen J, McFarland C, Erlich H . Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 1995; 85: 1954–1963.

    CAS  PubMed  Google Scholar 

  21. Iannone R, Casella JF, Fuchs EJ, Chen AR, Jones RJ, Woolfrey A et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003; 9: 519–528.

    Article  PubMed  Google Scholar 

  22. Burroughs LM, Strob R, Leisenring WM, Pulsipher MA, Loken MR, Torgerson TR et al. Intensive postgrafting immune suppresssion combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. Bone Marrow Transplant 2007; 40: 633–642.

    Article  CAS  PubMed  Google Scholar 

  23. Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, Schulz A, Thrasher AJ, Mazzolari E et al. Long-term outcome following hematopoietic stem cell transplantation in Wiskott–Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and the European Group for Blood and Marrow Transplantation. Blood 2008; 111: 439–445.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA

    E Ozyurek, M J Cowan, M A Koerper, C C Dvorak & B N Horn

  2. Department of Pediatrics, Ondokuz Mayis University, Samsun, Turkey

    E Ozyurek

  3. Department of Surgery, University of California, San Francisco, San Francisco, CA, USA

    L-A Baxter-Lowe

Authors
  1. E Ozyurek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M J Cowan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M A Koerper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L-A Baxter-Lowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C C Dvorak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B N Horn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B N Horn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ozyurek, E., Cowan, M., Koerper, M. et al. Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders. Bone Marrow Transplant 42, 83–91 (2008). https://doi.org/10.1038/bmt.2008.89

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.89

Keywords

This article is cited by

Search

Advanced search

Quick links